X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Korean Company GenKOre Offering Genetic Base-Editing Tech

    Gene Silencing Alzheimers Drug, A World First, Shows Promise

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    Australia Falling Short In Biotech Research Funding – Study

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Viral Infections Curbed By Gene Scissors In Human Cells

    Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

    Neurodevelopmental Issue Leads To Testicular Cancer Risk

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

    The UK begins the biggest ever immunization program

    New Approach Brought By Singapore For Pneumococcal Vaccines

    New Gestational Diabetes Alliance By Birmingham University

    New Gestational Diabetes Alliance By Birmingham University

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    Omya enhances supply of active pharmaceutical ingredients

    Omya enhances supply of active pharmaceutical ingredients

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Korean Company GenKOre Offering Genetic Base-Editing Tech

    Gene Silencing Alzheimers Drug, A World First, Shows Promise

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    Australia Falling Short In Biotech Research Funding – Study

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Viral Infections Curbed By Gene Scissors In Human Cells

    Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

    Neurodevelopmental Issue Leads To Testicular Cancer Risk

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

    The UK begins the biggest ever immunization program

    New Approach Brought By Singapore For Pneumococcal Vaccines

    New Gestational Diabetes Alliance By Birmingham University

    New Gestational Diabetes Alliance By Birmingham University

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    Omya enhances supply of active pharmaceutical ingredients

    Omya enhances supply of active pharmaceutical ingredients

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Viral Infections Curbed By Gene Scissors In Human Cells

Content Team by Content Team
29th April 2023
in News, Research & Development
Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

It is still difficult to get to the bottom of viral illnesses. Although isolated medicines exist that block virus multiplication in human cells, they are a significant exception. Against this backdrop, Prof. Reinhard Klein’s from IMC Krems’ Department of Life Sciences’ research group members have now evaluated the potential of molecular technologies so as to control viral infections. The researchers employed a scientifically proven technology- CRISPR-Cas9 also known as gene scissors for targeted DNA alteration to massively lower adenovirus proliferation in human cell lines in cell culture.

This Nobel Prize-winning technology alters DNA segments in mammalian cells in a highly regulated manner. Prof. Klein notes that the goal was to investigate the possibilities of this technology for battling viral infections, such as adenovirus infections, which frequently cause disorders of the respiratory tract, digestive tract, and eyes. The idea here is to strike-off a portion of adenovirus DNA in infected human cell lines, preventing the viruses from reproducing.

As Prof. Klein says, the strategy was surprisingly successful, as they were able to reduce the number of infectious virus particles in human cell lines by up to three orders of magnitude under specific conditions. A result that verifies the method’s efficacy and reveals that this technology is also powerful enough to combat the vast number of viruses released in infected cells during some viral illnesses.

This accomplishment was due to the combination of various measures. The initial step was to choose the viral DNA sequence that would be targeted by the CRISPR-Cas9 system. The team chose the virus’s E1A section, which is particularly significant at the start of the viral replication cycle. Prof. Klein claims that by effectively stopping viral replication, researchers were able to keep the total amount of viral DNA in the cells low enough for the CRISPR-Cas9 system to function at all. The researchers were concerned about the probable amount of viral DNA in the cells at the start of the investigation. After all, if the viruses proliferated at a significant rate, the CRISPR-Cas9 system would simply surpass its limits. However, the inactivation of E1A, which is crucial for the massive increase of viral DNA in infected cells, prevented this.

The use of a variety of so-called guide RNA nucleic acid strands that allow targeting of the DNA target sequence was a second measure that contributed to the substantial inhibition of viral multiplication. As a result, the adenovirus E1A gene was silenced more effectively, increasing the possibility that the virus would be unable to multiply.

Even at low doses, a combination with the DNA synthesis-inhibiting medication Cidofovir improved viral replication inhibition. The amplification effect occurs when viral DNA replication is impeded at two separate levels: first, CRISPR-Cas9 reduces the quantity of functional E1A product in the cell, and then cidofovir inhibits any remaining viral DNA replication.

The findings of the widely acclaimed study at IMC Krems highlight CRISPR-Cas9’s broad applicability and the possibilities of employing the technology to inactivate viruses. A major future application against viral infections is thus theoretically possible. However, Prof. Klein adds that if this technique is to be used for the treatment of viral infections in the future, numerous other concerns must first be answered and technical barriers addressed. As a result, while an application is still a long way off, the theoretical possibility has been proven.

Previous Post

Neurodevelopmental Issue Leads To Testicular Cancer Risk

Next Post

Australia Falling Short In Biotech Research Funding - Study

Related Posts

Korean Company GenKOre Offering Genetic Base-Editing Tech
Drug Development

Gene Silencing Alzheimers Drug, A World First, Shows Promise

29th April 2023
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Australia Falling Short In Biotech Research Funding – Study

29th April 2023
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment
News

Neurodevelopmental Issue Leads To Testicular Cancer Risk

27th April 2023
Tumors Can Get Destroyed By Bacteria-Aid To Immune System
Drug Development

Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

27th April 2023
DoKaSch Temperature Solutions and Japan Airlines sign Master Rental Agreement
News

United Cargo – after Opticooler RAP, now also Opticooler RKN certified

26th April 2023
The UK begins the biggest ever immunization program
News

New Approach Brought By Singapore For Pneumococcal Vaccines

26th April 2023
Next Post
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

Australia Falling Short In Biotech Research Funding - Study

Latest News

Korean Company GenKOre Offering Genetic Base-Editing Tech
Drug Development

Gene Silencing Alzheimers Drug, A World First, Shows Promise

29th April 2023
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Australia Falling Short In Biotech Research Funding – Study

29th April 2023
Catalent acquires cell and gene therapy-focused MaSTherCell for $315m
News

Viral Infections Curbed By Gene Scissors In Human Cells

29th April 2023
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment
News

Neurodevelopmental Issue Leads To Testicular Cancer Risk

27th April 2023
Tumors Can Get Destroyed By Bacteria-Aid To Immune System
Drug Development

Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

27th April 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In